DCTH
Delcath Systems, Inc.
DCTH has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has a slight edge over DCTH overall, supported by stronger fundamentals.
DCTH Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
DCTH's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
DCTH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 117x | $18.66 | -13% |
| Current | 134x | $21.38 | — |
| Fair | 166x | $26.50 | +24% |
| Forward | 1,071x | $21.38 | — |
| Expensive | 1,435x | $230 | +974% |
Historical ranges are pointers, not guarantees.
DCTH's PE is in its cheap range at 134x. On analysts' estimates for next year's earnings, today's price would be 1071x, in its fair range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over DCTH in the historical PE scenario, which offers more potential upside but is not a forecast.
DCTH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect DCTH to return to profit, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over DCTH on the outlook, with more favorable valuation expectations.
DCTH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.02 | -88% |
| Q3 2026 | $0.16 | +167% |
| Q2 2026 | $0.01 | -90% |
| Q1 2026 | $0.01 | +$0.46 |
| Q4 2025 | $0.07 | +$1.00 |
| Q3 2025 | $0.06 | +$1.38 |
| Q2 2025 | $0.10 | +$2.62 |
| Q1 2025 | -$0.45 | +$2.17 |
| Q4 2024 | -$0.93 | +$2.01 |
DCTH has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
DCTH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $35.1M | +71% |
| Q2 2026 | $29.1M | +21% |
| Q1 2026 | $25M | +26% |
| Q4 2025 | $20.7M | +37% |
| Q3 2025 | $20.6M | +84% |
| Q2 2025 | $24.2M | +211% |
| Q1 2025 | $19.8M | +530% |
| Q4 2024 | $15.1M | +2701% |
DCTH has the edge over OSCR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +22 points |
| Q2 2026 | 8.2% | -2.5 points |
| Q1 2026 | -6.5% | -9.8 points |
| Q4 2025 | -11% | -31 points |
| Q3 2025 | -1.9% | +9.3 points |
| Q2 2025 | 11% | +61 points |
| Q1 2025 | 3.3% | +331 points |
| Q4 2024 | 20% | +2117 points |
DCTH has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
DCTH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.9M | +60% |
| Q2 2026 | $5.2M | -24% |
| Q1 2026 | $287K | -86% |
| Q4 2025 | $7.7M | +$8.9M |
| Q3 2025 | $4.3M | +$8.2M |
| Q2 2025 | $6.9M | +$11.4M |
| Q1 2025 | $2.1M | +$11.7M |
| Q4 2024 | -$1.2M | +$7M |
DCTH has burned cash in most quarters: $20M over the past year, up 67% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
DCTH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.2% | +1.3M shares |
| 1 year | +2.4% | +963K shares |
| 3 years | +229% | +28.6M shares |
| 5 years | +514% | +34.3M shares |
DCTH has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $11,000 |
| Q1 2026 | $3M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
DCTH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -9.0x | Net Cash |
| Q4 2025 | -44.2x | Net Cash |
| Q3 2025 | -6.8x | Net Cash |
| Q2 2025 | -6.5x | Net Cash |
DCTH has the edge over OSCR on leverage, with a lower net debt burden relative to earnings.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
DCTH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 76.6 | Overbought |
| Stochastic | 60.2 | Neutral |
DCTH's weekly RSI is 77 (overbought) and its Stochastic is 60 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
DCTH PE vs Healthcare Sector
| Metric | DCTH | Sector median | Relative |
|---|---|---|---|
| PE | 134x | 26x | 417% above |
| PE % | 26 | 29 | 3 pts below |
DCTH is trading at 134x earnings, a 417% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over DCTH on valuation relative to its sector.
DCTH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $15.6 | 37% above |
| 20 week MA | $15.1 | 41% above |
| 50 week MA | $12.2 | 75% above |
| 100 week MA | $12.3 | 73% above |
| 200 week MA | $9.19 | 133% above |
DCTH is in an uptrend: it's above all five of its weekly moving averages, and 133% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
DCTH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $24.0 | $17.1 | -29% |
| 2021 | $17.1 | $8.45 | -51% |
| 2022 | $8.45 | $3.59 | -58% |
| 2023 | $3.59 | $4.16 | +16% |
| 2024 | $4.16 | $12.0 | +188% |
| 2025 | $12.0 | $10.3 | -14% |
| 2026 YTD | $10.3 | $21.4 | +108% |
DCTH's yearly returns have swung widely, from +188% in 2024 to −58% in 2022. It's up 108% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over DCTH on returns for 2026, with the stronger performance.